Arch Oncology, Inc.
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer. Our lead therapy is AO-176, an anti-CD47 antibody which is optimized for anti-cancer activity. We are advancing AO-176 in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with hematologic malignancies, both as monotherapy and in combination with standard therapies. Our company is headquartered in Brisbane, CA and we have a research team based in St. Louis, MO. Our team is committed to our mission to develop new therapies for patients living with cancer.
We target CD47 differently, and given our lead therapy’s potential, we plan to develop AO-176 broadly. Backed by preclinical research and encouraging early clinical tolerability and activity, we are advancing AO-176 in Phase 1/2 clinical trials for patients with select solid tumors and hematologic malignancies.
AO-176 is an IgG2 CD47 targeted antibody, which blocks the “don’t eat me” signal enabled by CD47’s interaction with SIRPa and induces phagocytosis. In addition;
- AO-176 exhibits lower binding to normal cells in general and negligible binding to red blood cells
- AO-176 shows preferential binding to CD47 at acidic vs. physiologic pH, as seen in tumor microenvironments
- AO-176 induces programmed and immunogenic cell death